Suven Pharmaceuticals Ltd - 543064 - Closure of Trading Window
Intimation of Closure of Trading Window from 1st July, 202330-06-2023
30-06-2023
Suven Pharmaceuticals Ltd - 543064 - Disclosures under Reg. 29(1) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for UTI Mutual Fund12-06-2023
Suven Pharmaceuticals Ltd - 543064 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to Regulation 39(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and in terms of SEBI Circular No. SEBIIHO/MIRSD/MIRSD_RTAMB/P/CIR /2022/8 dated January 25, 2022, this is to inform you that the Company has received intimation from our RTA dated June 09, 2023 regarding issued a 'Letter of Confirmation' in lieu of share certificate(s) reported as lost/misplaced by the following shareholders(s).09-06-2023
Suven Pharmaceuticals Ltd - 543064 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript
Pursuant to Regulation 30 read with Para A of Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed the transcript of the earnings conference call for the quarter and year ended March 31, 2023 conducted after the meeting of Board of Directors held on May 25, 2023. The above information has been uploaded on the Company''s website at https://www.suvenpharm.com/index.php/investors/financial-info/quarterly-release This is for your information and record.02-06-2023
Suven Pharmaceuticals Ltd - 543064 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Pursuant to Regulation 30 read with Para A of Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and with reference to our Results conference call intimation dated May 19, 2023, that audio recording of the conference call for the quarter and year ended March 31, 2023 held on Friday, May 26, 2023, has been uploaded on the Company''s website at https://www.suvenpharm.com/index.php/investors/financial-info/quarterly-release This is for your information and record.26-05-2023
Suven Pharmaceuticals Results Earnings Call for Q4FY23
Conference Call with Suven Pharmaceuticals Management and Analysts on Q4FY23 Performance and Outlook. Listen to the full earnings transcript.26-05-2023
Suven Pharmaceuticals Ltd - 543064 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Pursuant to Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, please find enclosed the copies of the newspaper advertisements regarding to Financial Results of the Company for the quarter and year ended March 31, 2023. The advertisements as appeared today i.e. May 26, 2023 in Andhra Prabha (Telugu) and Business Standard. The above information will also be hosted on the website of the Company at: https://www.suvenpharm.com/index.php/investors/corporate-info/advertisements This is for your information and record.26-05-2023
Suven Pharmaceuticals Ltd - 543064 - Compliances-Reg.24(A)-Annual Secretarial Compliance
With reference to above subject, please find enclosed herewith the Annual Secretarial Compliance Report issued by Mrs. D. Renuka, Practicing Company Secretary, for the financial year ended 31st March, 2023, under Regulation 24A of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. CIR/CFD/CMD1/27/2019 dated 8th February, 2019 as amended from time to time. We request you to take this document on your record.26-05-2023
Suven Pharmaceuticals Ltd - 543064 - Disclosure Of Related Party Transactions Pursuant To Regulation 23(9) Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations, 2015 ("Listing Regulations")
Pursuant to Regulation 23(9) of Listing Regulations, please find enclosed disclosure of related party transactions for the half-year ended 31st March, 2023. This is for your information and record.25-05-2023
Suven Pharmaceuticals Ltd - 543064 - Outcome Of The Board Meeting
With reference to the above subject, we wish to inform you that the Board of Directors of the company, at its meeting held today i.e. May 25, 2023, has taken on record and approved the attached Audited Standalone and Consolidated Financial Statements of the Company prepared under IND AS for the quarter and year ending 31st March, 2023 pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 along with Auditors' Reports of the Statutory Auditors. Further, we are enclosing herewith the following documents: 1) Audited Standalone and Consolidated Financial Results for the quarter and year ended 31st March, 2023 along with Statement of Assets and Liabilities, Profit & Loss account and Cash Flow Statement. 2) Auditor's Reports on the financial results as mentioned above 3) Declaration in respect of Audit Reports with unmodified opinion and 4) Earnings Presentation of our company to investors25-05-2023